TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22773670
Drug: Conditioned with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioned with Prompt L‐pop self‐etching primer (Group IV)
Study: 21332825
Drug: Propiverine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine (20 mg once daily)
Study: 3918688
Drug: Omeprazole 30
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 30 mg daily
Study: 19861577
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline CTC (three or more CTC per 7.5 ml of blood)
Study: 19861577
Drug: High CTC
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CTC at 1-2 weeks after the start of treatment
Study: 20384600
Drug: Venlafaxine 150
Normalized name: venlafaxine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 150 mg
Study: 27859267
Drug: Buspirone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 20 mg
Study: 8862936
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg i.v. on day 1 followed by 7 days oral treatment with one 15 mg tablet daily
Study: 8862936
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg i.m. on day 1 followed by 7 days treatment with one 100 mg slow release tablet daily
Study: 1442760
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel patch (10% lidocaine base with 3% glycyrrhetinic acid) applied for 60 minutes
Study: 1442760
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel patch
Study: 3899624
Drug: Flunarizine at
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine at doses of 0, 10, 15, 20, and 25 mg daily
Study: 20051836
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) (5,000 U per catheter line)
Study: 10193952
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2 on Day 1) and Etoposide (100 mg/m2 on Days 1, 3, and 5 or Days 4, 6, and 8 every 3 weeks)
Study: 229146
Drug: Flurazepam hydrochloride
Normalized name: Flurazepam Hydrochloride
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurazepam hydrochloride (15 mg)
Study: 19756530
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg)
Study: 11243489
Drug: Scopolamine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.6 mg/70 kg)
Study: 3488532
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (600 mg, five times a day for ten days)
Study: 30037498
Drug: Adjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant concurrent chemo-radiotherapy (CCRT)
Study: 30037498
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (CA)
Study: 12452227
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.5 per cent bupivacaine
Study: 10077358
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Testosterone TTS type 1
Study: 10077358
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Testosterone TTS type 1
Study: 10077358
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Testosterone TTS type 2
Study: 2149492
Drug: Teicoplanin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (6 mg/kg every 24 h intravenously)
Study: 6112931
Drug: DSCG (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSCG (40 mg)
Study: 31168938
Drug: BP +
Normalized name: Betamethasone phosphate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BP + DU therapy
Study: 27282077
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP)
Study: 30093398
Drug: Dasatinib therapy
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib therapy
Study: 20076861
Drug: Lumiracoxib 400mg
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 400mg administered orally 60 minutes before surgery
Study: 20076861
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally 60 minutes before surgery
Study: 17630037
Drug: Single-agent fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-agent fluorouracil (with levofolinate over 48 h every 2 weeks) until failure, then single-agent irinotecan (Control group A)
Study: 17630037
Drug: Fluorouracil until
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil until failure, then combination chemotherapy (Strategy B)
Study: 17630037
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy from the outset (Strategy C)
Study: 15001463
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (15 g)
Study: 15001463
Drug: Noncaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncaffeinated coffee (15 g) (control)
Study: 11157320
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (0.9% Ca by wt, 0.9 g Ca/d)
Study: 3049266
Drug: Terguride 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terguride 1.0 mg
Study: 3049266
Drug: Terguride 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terguride 0.25 mg
Study: 29738412
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (oCEE)
Study: 29738412
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol (tE2)
Study: 20044749
Drug: Replacement per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement per kilogram of lean body mass (LBM) (2.5 mcg/kg LBM per day)
Study: 20044749
Drug: Replacement per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement per kilogram of body weight (1.6 mcg/kg body weight per day)
Study: 12869973
Drug: Prompt L
Normalized name: Konsyl Senna Prompt Laxative 500mg-9mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L Pop
Study: 10501340
Drug: 6-month supervised
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month supervised exercise renal rehabilitation program (group A) consisting of three weekly sessions of aerobic training
Study: 2027146
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of Sea Bands every 2 hours.
Study: 883006
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy
Study: 29903274
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention with eggs and milk (200 g school milk and 50 g halogen eggs per school day)
Study: 27087059
Drug: Tocilizumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (4 or 8 mg/kg IV) + methotrexate
Study: 25144847
Drug: Intraoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative administration of a single dose of ropivacaine (n=33)
Study: 25144847
Drug: Conservative pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative pain therapy (n=34)
Study: 11477844
Drug: Renshen Guipi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renshen Guipi Pill (RSGPP)
Study: 7662344
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding started on the 7th postoperative day
Study: 7662344
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding started on the 14th postoperative day
Study: 2665180
Drug: Low-dose iron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iron supplement containing heme iron and non-heme iron (18-20 mg iron per day) for six months
Study: 2665180
Drug: Low-dose iron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iron supplement containing non-heme iron (18-20 mg iron per day) for six months
Study: 2665180
Drug: All supplements
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All supplements (including heme and non-heme iron)
Study: 30522750
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy plus antispasmodic medication
Study: 23786774
Drug: Prophylactic paracetamol
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic paracetamol (125 mg or 250 mg suppositories based on body weight) administered at vaccination and at 6-8 hour intervals thereafter
Study: 19837254
Drug: Prophylactic paracetamol
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic paracetamol
Study: 22117715
Drug: Manual instrumentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual instrumentation using K files (Dentsply/Maillefer) by crown‐down technique, cervical preparation with Gates‐Glidden #1 and #2 burs, and final preparation with ProTaper F2 and F3 rotary files
Study: 15327448
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg oral misoprostol every 6 h for 48 h
Study: 9102248
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 45 ml of NaPh taken at 6 p.m. the day before and at 6 a.m. on the morning of examination
Study: 9102248
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 3 liters of PEG solution taken at 2 p.m. the day before examination
Study: 9102248
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 45 ml of NaPh solutions taken at 7 a.m. and 7 p.m. the day before examination
Study: 8257144
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of ciprofloxacin (regimen A)
Study: 8257144
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of ciprofloxacin (regimen B)
Study: 30035560
Drug: 8-week somatic-focused
Normalized name: BOS TAURUS SOMATIC NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week somatic-focused culturally adapted cognitive-behavioral therapy (CBT)
Study: 31801679
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg/d
Study: 11799102
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg/d
Study: 8454478
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (Radiotherapy and Split course radiotherapy plus chemotherapy)
Study: 22589472
Drug: Deferasirox 5
Normalized name: deferasirox 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox 5 mg/kg/d
Study: 22589472
Drug: Deferasirox 10
Normalized name: Deferasirox 100 mg dispersible oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox 10 mg/kg/d
Study: 18184893
Drug: PedsQL paper-and-pencil
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PedsQL paper-and-pencil mode of administration
Study: 10648326
Drug: Control (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (40 mL 1.5% mepivacaine and saline)
Study: 27138187
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg (AT20)
Study: 17663731
Drug: Dalteparin 5000
Normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5000 U s.c. daily until 20 weeks and then 5,000 U s.c. q12 h until >37 weeks
Study: 15643099
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oxazepam
Study: 12200754
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion at rates of 6 and 8 ng.kg(‐1).min(‐1)
Study: 2181991
Drug: Control (observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (observation for 18 months without active treatment)
Study: 436305
Drug: Sulpiride infusion
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride infusion (intravenous)
Study: 436305
Drug: Oral sulpiride
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sulpiride treatment for 5 days
Study: 31200756
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HS, 7.3% NaCl) infused at 5 ml/kg ideal body weight
Study: 25596270
Drug: Intravenous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous bortezomib
Study: 23990499
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) chemotherapy administered intravenously for 6 weeks
Study: 835781
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) chemotherapy
Study: 21183418
Drug: Lovastatin (20‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20‐60 mg/day), hypolipidemic diet and physical training
Study: 15260910
Drug: Pindolol (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (maximum dose 20 mg b.i.d.)
Study: 11417267
Drug: GHB-ethanolamide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB-ethanolamide (150 mg/kg i.v. followed by 150 mg/kg/h)
Study: 11417267
Drug: Midazolam (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.025 mg/kg i.v. followed by 0.025 mg/kg/h)
Study: 9023466
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 or 50 mg)
Study: 12943873
Drug: Gemcabene 300
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcabene 300 mg
Study: 12943873
Drug: Gemcabene 900
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcabene 900 mg
Study: 10078400
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg bupivacaine 0.5% (B0.5%)
Study: 7675271
Drug: HBO +
Normalized name: Hib (HbOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO + NAC (1800 mg/day)
Study: 2149501
Drug: Aminoglutethimide low
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide low dose (125 mg bid)
Study: 2149501
Drug: Hydrocortisone alone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone alone (20 mg bid)
Study: 7020916
Drug: DTIC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC therapy in patients who developed thrombocytopenia
Study: 30882596
Drug: Taking antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking antihypertensive medications
Study: 29941057
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil (AL) 882 mg
Study: 23298824
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplement (5000 IU/day)
Study: 15181054
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg/d)
Study: 16569732
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 mg/d)
Study: 11729370
Drug: Oral medications
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medications other than sulfonylureas (n=17)
Study: 11729370
Drug: Insulin (n=28)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (n=28)
Study: 9256570
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (computer‐based behavioral self‐control training)
Study: 9256570
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (computer‐based behavioral self‐control training after a 10-week waiting period)
Study: 16368826
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg/d PO
Study: 16368826
Drug: Gabapentin 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1.2 g/d PO
Study: 16368826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rofecoxib 50 mg/d and gabapentin 1.2 g/d PO
Study: 14569096
Drug: ACEI (fosinopril;
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (fosinopril; 20 mg/d)
Study: 14569096
Drug: ARB (irbesartan;
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (irbesartan; 150 mg/d)
Study: 8876513
Drug: Low protein‐energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein‐energy supplement (nonsupplemented children)
Study: 2142323
Drug: Multidisciplinary inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary inpatient treatment for 4-6 weeks
Study: 74141
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy with low doses of Vinblastine and subsequent chemotherapy based on 99m‐Tc ‐‐labelled Bleomycin uptake
Study: 74141
Drug: Chemotherapy based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy based on individual Tc‐Bleomycin uptake curves
Study: 74141
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in 23 patients with previously untreated T3 tumors
Study: 74141
Drug: Chemotherapy overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy overall
Study: 28434097
Drug: Complementary/integrative medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary/integrative medicine (CIM) treatments
Study: 23958407
Drug: Calcium (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (2.0 g as calcium carbonate) and Calcium plus vitamin D3 (800 IU) pooled
Study: 23958407
Drug: Calcium (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (2.0 g as calcium carbonate)
Study: 29078817
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg)
Study: 12592236
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogens/2.5 mg medroxyprogesterone acetate
Study: 2569996
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg acrivastine administered three times daily
Study: 2569996
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg hydroxyzine administered three times daily
Study: 25566930
Drug: Edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 15 mg (off-dialysis)
Study: 17239355
Drug: D-amphetamine 20
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine 20 mg
Study: 10353581
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy
Study: 8607726
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target prothrombin time ratio, 1.3 to 1.8; approximate international normalized ratio, 2.0 to 4.5)
Study: 8607726
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg daily, enteric coated)
Study: 28591763
Drug: Ethanol 30
Normalized name: ethanol 30 % Medicated Liquid Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 30 g
Study: 28591763
Drug: Ethanol 6
Normalized name: ethanol 6.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 6 g
Study: 28591763
Drug: Ethanol 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 12 g
Study: 26396030
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis for basal ganglia ICH and small (<30 mL) ICH
Study: 23408163
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication reviews
Study: 23408163
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pharmacist-led medication reviews)
Study: 15234143
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide (250 mg)
Study: 12498856
Drug: Topical apraclonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical apraclonidine 1%
Study: 29808523
Drug: Robot-assisted training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted training (RAT) plus physical therapy
Study: 29808523
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy only (Control)
Study: 25151920
Drug: Standard iodinated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard iodinated contrast volume coronary CT angiography (SCCTA) with 80 mL iodinated contrast